EZH2 and cancer: Dysregulation of H3K27me3 is frequently observed in many types of cancers, and overexpression of EZh2 or mutations in the SET domain of EZH2 have been reported in lymphomas, causing an increase of H3K27me3 (Pawlyn et al. 2017; Nienstedt et al. 2018).